

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: YAMADA, Yoshiji, et al.

Group Art Unit: 3762

Serial No.: 10/517,605

Examiner: Not Yet Assigned

Filed: December 21, 2004

P.T.O. Confirmation No.: 1240

For. METHOD OF DIAGNOSING RISK OF MYOCARDIAL INFARCTION

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.56

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

February 22, 2006

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. In compliance with applicants duty of disclosure under 37 C.F.R. 1.56, enclosed herewith is a copy of the Supplementary European Search Report along with copies of the references cited therein. The Supplementary European Search Report was cited during the prosecution of the corresponding European patent application No. 03712817.0 (PCT/JP0303477).

The undersigned hereby certifies

XX that each item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart application and that this commination was not received by any individual designated in 37 CFR § 1.56(c) more than thirty days prior to the filing of this statement.

No fee or certification is required in connection with this Information Disclosure Statement,

since it is being submitted prior to the issuance of a first official action on the merits or expiration

of the three month period following the filing date or the entry of the national stage of the above-

captioned application.

The above information is presented so that the Patent and Trademark Office can, in the first

instance, determine any materiality thereof to the claimed invention. It is respectfully requested that

the information be expressly considered during the prosecution of this application, and that the

documents cited in the attached Form PTO-1449 be made of record therein and appear on the first

page of any patent to issue therefrom.

In the event that any fees are due in connection with this paper, please charge our Deposit

Account No. 01-2340.

Respectfully submitted,

ARMSTRONG, KRATZ, QUINTOS, HANSON & BROOKS, LLP

> Agent for Applicants Reg. No. 42,573

DAG/rk Atty. Docket No. 040677

Suite 1000 1725 K Street, N.W. Washington, D.C. 20006

(202) 659-2930

23850

PATENT TRADEMARK OFFICE

Enclosures: PTO-1449; Supplementary European Search Report; References (13)

FEB 2 2 2006

INFORMATION Docket No. 040677 Serial No. 10/517,605

DISCLOSURE
CITATION
PTO-1449 Filing Date: December 21, 2004 Group Art Unit: 3762

U.S. PATENT DOCUMENTS

Examiner Initial		Document No.	Name	Date	Class	Subclass	Filing Date (If appropriate)
/KH/	AA	2005-0089914	Yamasaki	04/28/2005			

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Translation (Yes or No)
/KH/	AC	01/79234	10/25/2001	PCT	·
/KH/	AD	91/13075	09/05/1991	PCT	Abstract only.
	AE	01/18250	03/15/2001	PCT	0.11
/KH/	AF	03/087360	10/23/2003	PCT	Abstract only.
	AG				

OTHER DOCUMENTS

/KH/	AH	PASTINEN, T., et al. "Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population;" <i>Human Molecular Genetics</i> ; Vol. 7, No. 9; pp.1453-1462 (1998).
/KH/	AI	LI, A., et al. "Relationship of the C242T p22phox Gene Polymorphism to Angiographic Coronary Artery Disease and Endothelial Function;" American Journal of Medical Genetics; Vol. 86, pp.57-61 (1999).
/KH/		RAURAMAA, R., et al. "Stromelysin-1 and Interleukin-6 Gene Promoter Polymorphisms Are Determinants of Asymptomatic Carotid Artery Atherosclerosis;"
	AJ	Arterioscler Thromb Vasc Biol.; Vol. 20; pp.2657-2662 (2000).
/KH/	AK	HUMPHRIES, S., et al. "The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study," *Atherosclerosis*; Vol. 139, pp.49-56 (1998).
Examiner		//Kenneth Horlick/ Date Considered 05/28/2008



INFORMATION DISCLOSURE CITATION PTO-1449

Atty. Docket No. 040677	Serial No. 10/517,605
Applicant(s): YAMADA, Yoshiji, et	al.
Filing Date: December 21 2004	Group Art Unit: 3762

U.S. PATENT DOCUMENTS

Examiner Initial		Document No.	Name	Date	Class	Subclass	Filing Date (If appropriate)
	BA						
	BB						

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Translation (Yes or No)
 вс				
 BD				

OTHER DOCUMENTS

		(2002).
/кн/	вн	GRUTTERS, J., et al. "Increased Frequency of the Uncommon Tumor Necrosis Factor-857T allele in British and Dutch Patients with Sarcoidosis;" AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE; Vol. 165, pp.1119-1124
/KH/	BG	YAMADA, Y., et al. "PREDICTION OF THE RISK OF MYOCARDIAL INFARCTION FROM POLYMORPHISMS IN CANDIDATE GENES;" The New England Journal of Medicine; Vol.347, No. 24, pp. 1916-1923 (2002).
/KH/	BF	BOEKHOLDT, S., et al. "Genetic Variation in Coagulation and Fibrinolytic Proteins and Their Relation With Acute Myocardial Infarction;" Circulation; Vol. 104, pp.3063-3068 (2001).
/KH/	ВЕ	YE, S., et al. "Progression of Coronary Atherosclerosis Is Associated with a Common Generic Variant of the Human Stromelysin-1 Promoter Which Results in Reduced Gene Expression;" <i>The Journal of Biological Chemistry</i> ; Vol. 271, No. 22. pp.13055-13060 (1996).

05/28/2008